Data from both Western countries and China have indicated a shift trend of hospitalization rates for acute myocardial infarction (MI) away from ST-segment elevation MI (STEMI) toward rising rates of non-STEMI (NSTEMI). [1] [2] [3] Older adults have the highest incidence, prevalence, and adverse outcomes of NSTEMI. With the trend of population aging all over the world, this high-risk cohort is increasing accordingly. Evidence favoring an early invasive strategy over a conservative strategy for initially stabilized elderly patients with NSTEMI has accumulated in the latest decades. [4] [5] [6] [7] [8] Despite a lack of data on elderly patients, consensus has been reached that the optimal timing of early invasive strategy was b24 hours, especially after the publication of the Timing of Intervention in Acute Coronary Syndromes (TIMACS) trial in 2009. 9 On the basis of these randomized controlled clinical trials (RCTs), the updated practice guidelines recommend the use of an early (b24 hours) invasive strategy in this high-risk group of patients aged ≥75 years of age if no contraindication exists. 10, 11 The rationale for an early invasive strategy is to stabilize the culprit lesion through early revascularization. However, it is always a great concern that the possible benefit of early revascularization may be balanced with the higher incidence of comorbidities and risk for bleeding complications typical of the elderly. As a matter of fact, a sizeable gap does exist between guideline recommendations and their application in real-world clinical practice, particularly for elderly patients in China. Recent registry data revealed that a large proportion of index percutaneous coronary interventions (PCIs) for initially stabilized elderly patients with NSTEMI were routinely deferred to N72 hours after admission currently across China. 12 A deferred invasive strategy aims to stabilize the culprit lesion using antithrombotic agents as a pretreatment to facilitate delayed revascularization and theoretically may be of potential benefit to elderly patients. Because no other country has ever applied such a routinely deferred approach, the efficacy and safety of such a unique deferred practice pattern remain to be further established. Therefore, taking standard early invasive strategy (b24 hours) as the active control, we designed the present multicenter, nationwide, and noninferiority-designed RCT to examine the noninferiority of a deferred invasive approach (N72 hours) in the elderly patients with NSTEMI.
Methods

Organizational framework
The project is organized and conducted by Fuwai Hospital, National Center for Cardiovascular Diseases of China (NCCD). An invitation to participate in the study was e-mailed by the department of coronary diseases of Fuwai Hospital to centers across different regions of mainland China without an interventional program involving elderly patients with NSTEMI. These centers should meet the following required standards: (1) volume of PCI exceeding 500 cases per year, (2) capable of performing emergent PCI independently, and (3) willing to consecutively recruit and randomize patients for the present study. The principal investigator is responsible for all aspects of the project, including the design, conduct, and report of the research project. The Scientific Committee, which consists of experienced clinical trialists and cardiology experts from China, helps to ensure the scientific and rational design of the study and supervises randomization, data collection, quality control, and data analysis. The Data Monitoring Committee is in charge of data quality evaluation and supervision. As an open study, there is an Independent Event Committee to adjudicate events. Data management and statistical analyses are managed by Medical Research and Biostatistics Center, NCCD. Each center has its own local study group, including a local principle investigator, a research coordinator, investigators, research assistants, and a local quality control person.
Grant support
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Ethical review
Institutional review board approval was granted by the Ethics Committee of Fuwai Hospital, NCCD, China, on June 14, 2016. The approved study protocol and related materials, such as consent forms and case report forms (CRFs), are submitted to the participating centers. All centers received institutional review board approval from their own ethics committees or accept central ethics approval. The protocol was registered on the ClinicalTrials.gov (Identifier: NCT02900001) on August 21, 2016.
Patient eligibility
Consecutive patients ≥75 years of age with the diagnosis of acute NSTEMI admitted to the emergency departments, CCUs, or wards of cardiology of participating centers are eligible for enrollment of registration provided they meet the criteria for acute NSTEMI and agree to participate in the registration study. The criteria of acute NSTEMI in our study refer to the third universal definition of MI 13 : (1) detection of a rise and/or fall of cardiac biomarker values (we specifically require cardiac troponin [cTn] with at least 1 value above the 99th percentile upper reference limit (URL); (2) symptoms of ischemia and/or new or presumed new significant ST-segment T-wave changes (ie, ST-segment depression of ≥1 mm or transient ST-segment elevation or T-wave inversion of N3 mm). Patients who present to hospital within 24 hours after the onset of symptoms are eligible for randomization. A signed informed consent form for registration or randomization should be obtained from patients or their immediate relatives. The exclusion criteria for randomization are listed in Table I .
Randomization and registry procedure
A patient log for all NSTEMI patients admitted to the participating centers will be available at the centers to check their consecutivity throughout the enrollment of the study. All patients who meet the inclusion criteria and had signed the appropriate consent form were registered through a secure, password-protected, Web-based electronic data capture system (http://www.CAMIRegistry.org) as in China Acute Myocardial Infarction (CAMI) Registry. 14 For patients who are eligible for randomization, their information will be entered into the Interactive Web Respond System built up and tested beforehand. Each enrolling center has its own unique account and password, and the treatment strategy will be released immediately after confirmation of the completeness of input information. This system ensures allocation concealment, and once a treatment strategy is released, the investigator cannot delete or alter any items of the patient's information. To avoid biases, randomized block design is applied to generate blind codes in advance to make sure that the ratio of patients assigned to early group and deferred group in each center is identical to the overall ratio (1:1).
Randomized treatment strategies
All patients eligible for randomization will be allocated to one of the following arms according to the results of central randomization: (A) Deferred invasive strategy-Patients assigned to deferred invasive strategy will initially be treated conservatively using guideline recommended medication. Coronary angiography and appropriate revascularization should not be done in the index hospitalization until after 72 hours. Apart from urgent revascularization, coronary angiography for any other reason during the first 72 hours would be deemed as dropping out. (B) Early invasive strategy-Patients assigned to early invasive strategy will undergo coronary angiography as soon as possible (b 24 hours), and PCI should be performed immediately according to coronary anatomy, patient preference, and operators' skills. In principle, only culprit lesion should be intervened at the early phase. It is left to the discretion of corresponding physicians whether a staged complete revascularization should be performed or not. For patients who need coronary artery bypass grafting (CABG), the operation should be performed as soon as possible during the index hospitalization.
Measurements of cTn
Besides the immediate test on admission, cTn should be measured every 6-12 hours to capture the turning point. When a reinfarction is suspected from clinical signs or symptoms following the initial MI, an immediate remeasurement of cTn is required. A second sample should be obtained 3-6 hours later. For patients undergoing a PCI, cardiac troponins should be retested 6-12 hours after the procedure.
End points
The end points of the trial are adjudicated by an independent committee. The primary end point of the study (RCT and registry) is defined as a composite of all-cause mortality, nonlethal (re)MI, stroke, and urgent revascularization at 1 month and 12 months. Secondary outcome measures comprise the individual and composite of no reflow; severe recurrent ischemia; all-cause mortality; MI; stroke; urgent revascularization; or major bleeding at 1, 6, and 12 months.
Definitions of the end point components
All-cause mortality includes all deaths, regardless of whether or not the cause of death is determined. For the secondary analysis, all deaths will be assumed to be cardiovascular unless a noncardiovascular cause can be found.
Myocardial (re)infarction refers to an acute MI that occurs within 28 days of an incident or recurrent MI. 15 For the present study, cTn is required to make the diagnosis of MI instead of CK-MB. Diagnosis of MI requires cTn elevation greater than the URL with new symptoms and/or ECG changes. After PCI, cTn elevation must be N5× URL within 48 hours of the procedure. If the baseline cTn values are elevated and are stable or falling, then a rise of 20% is required for the diagnosis of PCI-related infarction. During the first 48 hours following CABG, diagnosis of CABG-related MI requires cTn values N10× 99th percentile URL occurring from a normal baseline cTn value.
Stroke is defined as any new neurologic deficit lasting N24 hours. Consultation of a neurologist for assessment of the functional status is required to confirm the diagnosis. Ischemic and hemorrhagic stroke should be distinguished. Fatal and disabling stroke will be counted in the primary end point of the study, whereas also nondisabling strokes will be counted in the secondary analyses.
Urgent revascularization is defined as coronary (any vessel) revascularization (any type PCI or CABG) decided within 24 h for reinfarction, refractory angina pectoris, No reflow is determined by angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (b50%), dissection, spasm, or apparent thrombus and angiographic documentation of a TIMI flow grade ≤ 2 at least 10 minutes after the end of PCI procedure.
Severe recurrent ischemia is defined as at least 1 episode of severe, prolonged pain at rest for more than 5 minutes with new ischemic ST-segment T-wave changes; or cTn rise not meeting criteria for MI; or need for unplanned coronary angiography, PCI, or CABG.
Bleeding is to be classified according to the Bleeding Academic Research Consortium scale. 16 Bleeding Academic Research Consortium type 3 to 5 bleeding will be considered as major bleeding in the secondary end point.
Concomitant medications
Generally, all other treatment besides the index coronary angiography and revascularization are conducted according to hospital routine in the participating centers and in line with current practice guidelines, including anticoagulants in the periprocedural period and the use of glycoprotein IIb/ IIIa receptor blockers. 11, 17, 18 It is noteworthy that a loading dose of aspirin (300 mg) and P2Y 12 inhibitors (clopidogrel 300 mg or ticagrelor 180 mg) should be given to the patients on admission in all centers, followed by aspirin of 100 mg and P2Y 12 inhibitors (clopidogrel 75 mg or ticagrelor 180 mg) daily. The duel-antiplatelet treatment for at least 1 year is recommended until the end of follow-up. Proton pump inhibitors are also recommended in all patients throughout the study. 19 Patients with use of oral anticoagulants or presenting with a condition (eg, atrial fibrillation) in which an anticoagulant should be initiated on admission are contraindicated to randomization in this study. The subsequent use for conditions that may develop during follow-up is left to the discretion of the attending physician as clinically indicated. β-Blockers, angiotensin-converting enzyme/receptor inhibitors, and statins should be given to each patient appropriately, unless a contraindication exists, which should be recorded clearly.
Follow-up
All surviving patients will be followed up to 1 year even if they have reached an end point of the study. Follow-up visits are planned at 30 days (±10 days), 6 months (±30 days), and 12 months (±30 days) postrandomization. If visits are not convenient for the patients, telephone contacts should be made to inquire all information related to the end points. However, a follow-up visit to hospital will be obligatory at 12 months. A 12-lead electrocardiogram and an echocardiography will be taken at the 12-month visit to check the differences of development throughout the study period. On Figure 1 The design of DEAR-OLD Study.
each visit, patients are invited to bring any documentation (discharge letter or copy of hospital records) related to new hospitalizations occurring after index hospital discharge. The overall protocol is summarized in Figure 1 .
Adverse events
In the present study, adverse events include inherent adverse events of MI and PCI. Besides the end point measures, thrombocytopenia, vascular access site hematoma requiring intervention/surgery, contrast-induced nephropathy, sepsis, and pulmonary embolism during the index hospital stay or leading to new admissions during follow-up will also be captured in the CRF.
Data collection and monitoring
Source data of medical records and related profile (eg, image of electrocardiogram and coronary angiography, echocardiography report, blood sample testing results) of each patient enrolled in this study will be scanned, copied, or recorded onto a CD and presented to a Web-based monitoring system. Specialized staff will ensure the integrity and confidentiality of these files. Required data for the present study will be collected in a Web-based CRF that have been programmed to minimize the number of imputing errors and missing entries. The system will also work as a reminder for the follow-up visits each time the investigator intends to enter data for a new patient or a visit. The study monitors will be in charge of visiting the centers in special cases for troubleshooting. A copy of the discharge summary of each patient enrolled in the study will be sent to the Chief Research Officer in charge of the study to check major events during index hospitalization and validate the clinical events related to the primary and secondary end points of the study.
Sample size
The sample size was calculated according to the guidance for industry sponsored trials by US Food and Drug Administration on the appropriate use of noninferiority study designs. 20 The primary end point event rates of previous studies concerning invasive strategy in elderly non-ST-elevation acute coronary syndrome (NSTE-ACS) patients aged ≥75 years were listed in Table II. 4,6-8 Taking into account factors like enrolled patients' age, risk profile, primary end point determination, and follow-up period, we estimated the primary event rate at 12 months of elderly patients with NSTEMI using conservative strategy at 40%. To determine the noninferiority margin (Δ), we anticipated an absolute reduction of 10% in event rate of early invasive arm compared with conservative strategy. The largest clinically acceptable difference in the risk reduction provided by the deferred approach compared with early invasive strategy was deemed to be half of the early invasive strategy's effect, so the noninferiority margin was set to be 5%. Based on these estimates, a sample size of 330 patients in each arm was determined with a 2-sided level of significance (α) of .05 and an estimated power (1 − β) of 80% using the formula listed below.
Considering a 3% loss in follow-up, a total of 696 patients is needed for randomization in this trial.
Statistical analysis
Estimation of the cumulative primary event rate will be done with the Kaplan-Meier method on an intention-to-treat basis. Log-rank test will be used to assess the significance of differences in event rates between groups. The Cox proportional hazards model will be used to estimate the treatment effect. The upper bound of the 95% CI of the hazard ratio of deferred invasive strategy versus early invasive strategy will be compared with the noninferiority margin for the noninferiority testing. 
Report of registry data
We will report the outcomes of the registry patients along with other patients with NSTEMI from all participating centers in CAMI Registry, which has been launched in 2013 and is still enrolling patients from 108 hospitals across China.
Planned timetable
The first patient of DEAR-OLD study was randomized on December 1, 2016. Up to the time of submission of this manuscript, 105 patients have been randomized (53 patients in the test arm, 52 patients in the active control arm) and 298 patients registered in 10 active centers that have started enrollment. Recruitment is expected to be completed by October 2018 and the last patient visit by October 2019. An interim safety analysis after 250 patients had completed at least 6 months of follow-up was planned. The main analysis should be reported by December 2019.
Discussion
The DEAR-OLD trial is a prospective, nationwide, multicenter, noninferiority-designed, open-label RCT to assess the efficacy and safety of a routinely deferred invasive strategy in comparison with an early invasive strategy for elderly patients with NSTEMI. The choice of a noninferiority design instead of a superiority design was mainly based on 2 factors: the established superiority of early invasive strategy to conservative strategy in elderly patients with NSTEMI and the lack of evidence of a routinely deferred invasive approach currently applied in China, which could be potentially as effective as early invasive strategy in such an old cohort of patients.
Numerous randomized trials had verified the superiority of early invasive strategy to conservative strategy in patients with NSTE-ACS, even in elderly patients ≥75 years of age. TACTICS-TIMI 18 was the first RCT that showed a reduction in death or MI with the early invasive strategy in patients with NSTE-ACS ≥75 years of age. (FIR) trials also showed that the long-term reduction in the composite of cardiovascular death or MI with the early invasive strategy compared with a conservative invasive strategy could be seen in patients with NSTE-ACS aged ≥75 years. 7 The Italian Elderly ACS trial was the first RCT specifically designed to determine the risk versus benefit ratio of an early aggressive approach among elderly patients with NSTE-ACS. Although it did not allow a definite conclusion about the benefit of an early invasive approach because of its limited power, it revealed a significant reduction of the primary end point in patients with elevated troponin on admission. 6 Soon afterward, the After Eighty study, the latest and properly powered RCT, explicitly verified the superiority of invasive strategy to a conservative strategy in very old patients (N80 years) with NSTE-ACS. 4 More recently, a meta-analysis of 4 randomized trials and 3 observational studies enrolling a total of 20,540 patients verified the superiority of routine early invasive therapy to conservative strategy in patients ≥75 years old presenting with NSTE-ACS. 21 Based on these robust evidences, the effectiveness of early invasive strategy in elderly patients with NSTEMI was established.
Despite the overwhelming evidence favoring early invasive approach over conservative strategy, a routinely deferred invasive approach is applied for patients with NSTEMI across mainland China. Recent data from the Improving CCC Project (Care for Cardiovascular Disease in China) revealed that only 26.3% of index PCIs in high-risk elderly patients with NSTE-ACS were performed within 24 hours, whereas 44.1% were done after 72 hours. 12 The data from CAMI Registry also showed that 83% of NSTEMI patients received an index revascularization after 72 hours from symptom onset and over 40% after 7 days. Elderly patients ≥75 years of age were delayed even more. No significant difference of in-hospital mortality was noticed between different timing of revascularization in these 2 separate registries, and the benefit of such a delayed revascularization over conservative treatment is still profound independent of age. The findings suggest further RCTs to specifically evaluate the efficacy and safety of such a deferred invasive approach in elderly patients with NSTEMI, which remains poorly explored. A deferred invasive strategy aims to stabilize the culprit lesion using antithrombotic agents as a pretreatment to facilitate delayed revascularization, and may potentially be of benefit to elderly patients in theory. Therefore, we choose a noninferiority design to test the hypothesis that a routinely deferred invasive approach is not inferior to early invasive strategy in elderly patients ≥75 years of age with NSTEMI.
Besides the urgent need of justification for such a deferred invasive approach applied in China, we also feel obliged to conduct the DEAR-OLD study for the lack of relevant evidence on elderly patients ≥75 years of age. Previous RCTs had been conducted to explore the optimal timing of routine invasive strategy in NSTE-ACS, although none of them was specifically designed for elderly patients ≥75 years of age. The main trials, as listed in Table III , showed high heterogeneity between studies in the effect of different timing of catheterization on mortality and occurrence of new MI. 9, [22] [23] [24] [25] [26] Among these trials, the TIMACS trial (subgroup analysis) and the Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients (RIDDLE-NSTEMI) study showed that early (b24 hours) or immediate (b2 hours) intervention appeared to provide a significant benefit in prevention of death, myocardial infarction, or stroke over a deferred strategy in patients with NSTEMI. 9, 26 However, many a study failed to demonstrate a definite benefit of an early invasive strategy over a deferred strategy in reducing mortality or new MI in general patients with NSTE-ACS. 9, 24, 25 Moreover, a series of meta-analysis on timing of routine invasive strategy for NSTE-ACS consistently showed a negative effect of routine early invasive intervention strategy (median time to catheterization ranged from 0.5 to 14.0 hours) in reducing the risk of death or myocardial infarction compared with a delayed approach (median time range from 18.3 to 86.0 hours). Only a potential to reduce rate of recurrent ischemia was observed in early invasive intervention. [27] [28] [29] [30] Although these evidences could not challenge the superiority of early invasive strategy b24 hours, the optimal timing of catheterization for NSTEMI remained far from certain, especially for elderly patients. The average time to angiography was 3 days in the After Eighty study, and such a "delayed" approach also achieved great benefit in such a cohort of patients aged over 80 years. 4 Since invasive management for elderly patients ≥75 years of age tends to be delayed for comorbidities and competing risk, whether a routinely deferred catheterization can be an alternative to the standard early approach for this cohort of patients is of our great concern.
So far, the only trial which set a deferred timing of catheterization as late as over 72 hours was the Intracoronary Stenting With Antithrombotic Regimen Cooling-Off (ISAR-COOL) trial (in 3 to 5 days), which was conducted in the early 2000s with only a small proportion of patients aged ≥75 years. 22 However, it failed to prove that "cooling-off" strategy could improve the outcome compared with immediate intervention in NSTE-ACS patients. Since then, all later RCTs of this kind have all set the timing of delayed intervention much earlier than 72 hours. However, all patients in the ISAR-COOL trial received glycoprotein IIb/IIIa inhibitor prior to or during PCI, and the loading dose of clopidogrel was 600 mg. Thus, the improved outcomes with early PCI as noted in ISAR-COOL could have been due to rigorous early use of antithrombotic and antiplatelet therapy along with early PCI, which would be much more rarely used in elderly patients ≥75 years of age. Moreover, with the fast development of antithrombotic treatment over the last decade, it may be a different picture regarding risks and benefits of such a prolonged antithrombotic pretreatment before invasive strategy. Different from ISAR-COOL trial, catheterization of the deferred arm can be done at any time after 3 days in the index hospitalization before discharge at doctor's discretion, mimicking the Chinese pattern of deferred invasive strategy. What is more, unlike the ISAR-COOL trial, we did not intend to challenge the superiority of early invasive strategy. In the lack of previous evidence favoring the deferred approach of N72 hours over early invasive strategy of b24 hours, we choose a noninferiority design to test the hypothesis that the deferred invasive strategy is not inferior to early invasive strategy, which may provide an alternative approach in elderly patients.
There is an ongoing U.K. trial, The British Heart Foundation Older Patients With Non-ST SEgmeNt elevatIOn myocaRdial Infarction Randomized Interventional TreAtment (SENIOR-RITA) Trial, also addressing the invasive strategy issue of elderly NSTEMI patients (ClinicalTrials.gov Identifier: NCT03052036). Similar to the Italian Elderly ACS trial and After Eighty study, the SENIOR-RITA trial was designed to compare time to cardiovascular death or nonfatal MI within 1 year from randomization between invasive and conservative strategy. However, different from these trials, the present DEAR-OLD trial takes early invasive strategy as the active control based on previous evidences and applies catheterization to each elderly patient enrolled in both arms. We intend to further investigate whether a routinely deferred invasive strategy is not inferior to an early strategy in elderly patients, which remains an issue of limited evidence.
The main obstacles that can be expected in the course of the present study are slow enrollment and lower-than-projected sample size which have also been shown in several previous trials comparing invasive strategies in elderly patients. 6, 25, 31 However, we estimated the sample size with full consideration of the high-risk profile, like the advanced age and elevated cTns, of patients to be enrolled in DEAR-OLD trial. The estimation of event rate was conservative. The large population of patients with NSTEMI in China and qualified high-PCI-volume clinical centers involved in the DEAR-OLD trial offer a unique advantage for us to ensure sufficient enrollment of patients in the limited time.
In conclusion, DEAR-OLD study is a Chinese population-oriented, prospective randomized clinical trial that will add important evidence of whether the routine deferred pattern of invasive management is noninferior to guideline-recommended early strategy in the elderly Chinese patients with NSTEMI or not.
